Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -53.66%. A quarter ago, it was expected that this genome editing company would post a loss of $0.51 per share when it actually produced a loss of $0.43, delivering a surprise of +15.69%.Over the last four quarters, the c ...